Raymond Mahan, MD
Internal Medicine · Rogers, ARNPI 1730137811
Payments from drug & device makers
Across 189 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$670
- Amgen$428
- GSK$423
- Johnson & Johnson$331
- Abbott$295
- Astellas Pharma US Inc$119
- plus $561 from 15 others
What the payments were for
- Food & beverage$2,816100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $670 |
| Amgen(2 entities) | 26 | $428 |
| GSK | 32 | $423 |
| Johnson & Johnson(2 entities) | 26 | $331 |
| Abbott | 14 | $295 |
| Astellas Pharma US Inc | 8 | $119 |
| Pfizer | 7 | $90 |
| Novartis | 6 | $84 |
| Merck | 6 | $75 |
| Novo Nordisk | 4 | $65 |
| Amarin Pharma, Inc. | 2 | $45 |
| Boehringer Ingelheim | 3 | $44 |
| Bristol Myers Squibb | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Sanofi Pasteur Inc. | 1 | $14 |
| UCB, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| AstraZeneca | 1 | $11 |
How this compares
$2,828 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 174 | $211,371 |
| JardianceEmpagliflozin | 132 | $172,656 |
| TrulicityDulaglutide | 66 | $116,760 |
| MounjaroTirzepatide | 80 | $113,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 106 | $92,967 |
| OzempicSemaglutide | 37 | $66,720 |
| XareltoRivaroxaban | 61 | $61,666 |
| FarxigaDapagliflozin Propanediol | 52 | $41,848 |
| MyrbetriqMirabegron | 47 | $29,662 |
| LinzessLinaclotide | 30 | $24,724 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $19,426 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $16,133 |
| Bydureon BciseExenatide Microspheres | 19 | $15,464 |
| JanuviaSitagliptin Phosphate | 11 | $15,453 |
| Spiriva RespimatTiotropium Bromide | 14 | $12,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $12 | $230,344146 claims |
| PfizerEliquis | $90 | $211,371174 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $44 | $185,301146 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $423 | $112,393141 claims |
| Novo NordiskOzempic | $65 | $66,72037 claims |
| Johnson & JohnsonXarelto | $331 | $61,66661 claims |
| AstraZenecaFarxiga, Symbicort | $11 | $53,17593 claims |
| MerckJanumet, Januvia | $75 | $31,58622 claims |
| Astellas Pharma US IncMyrbetriq | $119 | $29,66247 claims |
| AbbVieLinzess | $670 | $24,72430 claims |
| NovartisEntresto | $84 | $11,19517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Rogers
- Kathleen GannonRogers$450K
- Stuart BensonRogers$24K
- Douglas EddyRogers$9K
- Ruben TejadaRogers$6K
- Kristy JonesRogers$6K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
- Alexander KaczenskiLittle Rock$305K
- John HendersonSearcy$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.